Organon & Co. Decrease in Unrecognized Tax Benefits is Reasonably Possible
Organon & Co. (OGN) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $27.00 million as of 2022-12-31, per its 10-K filed 2024-02-26.
Discontinued › Notes › Income Taxes
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2024-02-26
- 2022-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $27.00M.
- 2021-12-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $15.00M; Decrease in Unrecognized Tax Benefits is Reasonably Possible as first filed $11.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible | Decrease in Unrecognized Tax Benefits is Reasonably Possible as first filed |
|---|---|---|
| 2022-12-31 | $27.00M 10-K · filed 2024-02-26 | |
| 2021-12-31 | $15.00M 10-K · filed 2023-02-27 | $11.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |